Maccura Biotechnology Co.Ltd

Shenzhen Stock Exchange 300463.SZ

Maccura Biotechnology Co.Ltd EBITDA Margin for the year ending December 31, 2023: 22.52%

Maccura Biotechnology Co.Ltd EBITDA Margin is 22.52% for the year ending December 31, 2023, a -26.06% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Maccura Biotechnology Co.Ltd EBITDA Margin for the year ending December 31, 2022 was 30.45%, a -18.24% change year over year.
Maccura Biotechnology Co.Ltd EBITDA Margin for the year ending December 31, 2021 was 37.25%, a 10.97% change year over year.
Maccura Biotechnology Co.Ltd EBITDA Margin for the year ending December 31, 2020 was 33.56%, a 18.10% change year over year.
Maccura Biotechnology Co.Ltd EBITDA Margin for the year ending December 31, 2019 was 28.42%, a -0.35% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

Shenzhen Stock Exchange: 300463.SZ

Maccura Biotechnology Co.Ltd

CEO	Mr. Wu Mingjian
IPO Date	May 28, 2015
Location	China
Headquarters	Hi-tech Zone
Employees	3,362
Sector	Healthcare
Industries Biotechnology 3D Printing Chemicals & Advanced Materials Cleaning Supplies Medical Instruments Personal Care Pharmaceuticals Plastics

Description

Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers. It also provides SARS-COV-2(COVID-19) products that includes nucleic acid detection kit and other products; glucometers; POCT products, such as fluorescence immunoassay analyzers, as well as colloidal gold kits; molecular diagnosis products, such as PCR kit; and pathology products. The company was incorporated in 1994 and is based in Chengdu, China.

Key trends

Past 5 years